Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3196-3203

  Mok, Tony ^a   Wu, Yi Long ^b   Lee, Jin Soo ^c   Yu, Chong Jen ^d   Sriuranpong, Virote ^e   Sandoval Tan, Jennifer ^f   Ladrera, Guia ^g   Thongprasert, Sumitra ^h   Srimuninnimit, Vichien ⁱ   Liao, Meilin ^j   Zhu, Yunzhong ^k   Zhou, Caicun ^l   Fuerte, Fatima ^m   Margono, Benjamin ⁿ   Wen, Wei ^o   Tsai, Julie ^o   Truman, Matt ^p   Klughammer, Barbara ^q   Shames, David S ^r   Wu, Lin ^o  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c National Cancer Center   (South Korea)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f PHILIPPINE GENERAL HOSPITAL   (Philippines)

^g Lung Centre of the Philippines   (Philippines)

^h Faculty of Medicine Chiang Mai University   (Thailand)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j SHANGHAI CHEST HOSPITAL   (China)

^k CAPITAL MEDICAL UNIVERSITY   (China)

^l SHANGHAI PULMONARY HOSPITAL   (China)

^m Rizal Medical Center   (Philippines)

ⁿ AIRLANGGA UNIVERSITY   (Indonesia)

^o ROCHE MOLECULAR SYSTEMS   (United States)

^p Roche Products Ltd   (Australia)

^q F HOFFMANN LA ROCHE LTD   (Switzerland)

^r GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIRCULATING FREE TUMOR DNA; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PLACEBO; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DNA; INTERCALATING AGENT; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PROCEDURES; PROTO ONCOGENE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DOUBLE-BLIND METHOD; ERLOTINIB HYDROCHLORIDE; FEMALE; GENES, ERBB-1; HUMANS; INTERCALATING AGENTS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84938399710     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2594     Document Type: Article

References (27)

1. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open-label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
4. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
5. Rosell R, Carcerency E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
6. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-8.
7. Sequist L, Yang J, Yamomoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
8. Paz-Ares L, Soulieres D, Moecks J, Bara I, Mok T, Klughammer B. Pooled analysis of clinical outcomes for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med 2014;18:1519-39.
9. Wu YL, Zhou C, Hu C, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUXLung 6): an open-label randomized phase 3 trial. Lancet Oncol 2014;15:213-22.
10. Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012;77:371-5.
11. Xu C, Zhou Q, Wu YL. Can EGFR TKIs be used in first-line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature-based meta-analysis. J Haematol Oncol 2012;5:62-77.
12. Newman A, Bratman S, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultra sensitive method for quantitating circulating tumour DNA with broad patient coverage. Nat Med 2014;20:548-54.
13. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasmaDNAsamples predict tumour response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
14. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007;97:778-84.
15. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum. J Thorac Oncol 2012;7:115-21.
16. Douillard J, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thoracic Oncol 2014;9:1345-53.
17. Kim H, Lee S, Hyun D, Lee MK, Lee HK, Choi CM, et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res 2013;32:50.
18. Courard S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Non invasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-ofconcept study from BioCAST/IFCT-1002. Clin Cancer Res 2014;20:4613-24.
19. Oxnard G, Paweletz G, Kuang Y, Mach S, O'Connell A, Messineo M, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
20. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7.
21. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, doubleblind trial. Lancet Oncol 2013;14:777-86.
22. Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, et al. Detection of EGFR mutations in plasma and biopsies from non-small-cell lung cancer patients by allele-specific PCR assays. BMC Cancer 2014;14:294.
23. An S, Chen Z, Su J, Zhang XC, Zhong WZ, Yang JJ, et al. Identification of enriched driver gene alterations in subgroups of non-small-cell lung cancer patients based on histology and smoking status. PLoS ONE 2012;7:e40109.
24. Kamat A, Bischoff F, Dang D, Baldwin MF, Han LY, Lin YG, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006;5:1369-74.
25. Ng K, Hillmer A, Chuah C, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18:521-8.
26. Bottcher S, Ritgeb M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30:980-8.
27. Leduc C, Moussa N, Faivre L, Biondani P, Pignon J, Caramella C, et al. Tumour burden and tyrosine kinase inhibitors (TKI) benefit in advanced non-small-cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (mEGFR) and ALK rearrangement (ALK+) [abstract 92O]. J Thorac Oncol 2014;9:S37.